3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
145
Lymphoma
104
Lymphoma, Large B-Cell, Diffuse
76
Sarcoma
62
Hodgkin Disease
46
Precursor Cell Lymphoblastic Leukemia-Lymphoma
38
Burkitt Lymphoma
35
Triple Negative Breast Neoplasms
31
Lymphoma, Non-Hodgkin
29
Lymphoma, Mantle-Cell
27
Leukemia
25
Neoplasms
22
Lymphoma, Follicular
22
Neoplasm Metastasis
21
Multiple Myeloma
21
Neuroblastoma
20
Carcinoma, Hepatocellular
18
Ovarian Neoplasms
16
Lymphoma, B-Cell
16
Liver Neoplasms
14
Urinary Bladder Neoplasms
12
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
12
Osteosarcoma
12
Lymphoma, T-Cell, Peripheral
11
Lymphoma, Large-Cell, Anaplastic
11
Inflammatory Breast Neoplasms
11
Breast Neoplasms, Male
11
Prostatic Neoplasms
10
Dendritic Cell Sarcoma, Interdigitating
10
Lymphoma, Large-Cell, Immunoblastic
9
Interventions
tazemetostat
1
relatlimab
1
durvalumab
1
brigimadlin
1
bintrafusp alfa protein, human
1
Nivolumab
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Tertiary Lymphoid Structures
×
Doxorubicin
×
Clear all
NCT04874311
2025-08-13
TRUST
Institut Bergonié
Phase 2
Recruiting
80 enrolled